Foghorn®-logo-color.jpg
Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer
September 03, 2024 07:00 ET | Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn®-logo-color.jpg
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September
August 28, 2024 07:00 ET | Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn®-logo-color.jpg
Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update
August 08, 2024 07:00 ET | Foghorn Therapeutics, Inc.
Topline Phase 1 dose escalation data for FHD-286 in combination with decitabine, in relapsed and/or refractory AML patients, anticipated in the fourth quarter of 2024 Dosing of first patient in a...
Foghorn®-logo-color.jpg
Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
May 28, 2024 07:00 ET | Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn®-logo-color.jpg
Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline
May 22, 2024 18:21 ET | Foghorn Therapeutics, Inc.
Positions company to further leverage strength of platform and advance programs through multiple data readouts and clinical value inflection points Strengthens balance sheet with cash, cash...
Foghorn®-logo-color.jpg
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
May 20, 2024 07:58 ET | Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (“Foghorn”) (Nasdaq: FHTX) today announced the pricing of a registered direct offering of 12,743,039 shares of its common...
Foghorn®-logo-color.jpg
Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
May 06, 2024 07:00 ET | Foghorn Therapeutics, Inc.
Dose escalation in FHD-286 combination trial in AML continues to progress with clinical data expected in the second half of 2024; potential to be a first-in-class oral broad-based differentiation...
Foghorn®-logo-color.jpg
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
April 16, 2024 07:00 ET | Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn®-logo-color.jpg
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
April 09, 2024 16:30 ET | Foghorn Therapeutics, Inc.
First-in class BRM (SMARCA2) selective inhibitor FHD-909 demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically; IND filing on track for Q2...
Foghorn®-logo-color.jpg
Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
April 05, 2024 07:00 ET | Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...